A Phase 2 interventional study of Febuxostat and IBI128 in Gout and Hyperuricemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.
Among the 49 studies in Gout with a site in China, this one is the 24th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 2, and was the 34th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Huashan Hospital · Sites in China
Ages 18–70
Shenyang Sunshine Pharmaceutical Co., LTD. · Sites in China
Ages 18–65
Shanghai Institute Of Biological Products · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 9 · Phase 3 10 · Phase 4 3
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is close to the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 93 across the 44 interventional studies, 350 across the 5 observational. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 3 studies filed under Gout — fewer than ten, so there is no comparison to draw.
5 of the studies in Gout with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07414394Phase 3Innovent Biologics Technology Limited (Shanghai R&D Center)Tigulixostat (IBI128) vs Febuxostat in Gout | 2027-04-30 |
| NCT06629376Shenyang Sunshine Pharmaceutical Co., LTD.Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia | 2026-12-20 |
| NCT06298071Shanghai Institute Of Biological ProductsA Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. | 2026-12-30 |
| NCT07587684Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Study of IN026 in Participants With Refractory Gout | 2027-08 |
| NCT07326839XueMei GuoOrlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in Gout with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.
This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria (brief):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablets, Once a day (QD), Per oral
Drug: Febuxostat
Tablets, Once a day (QD), Per oral
Drug: IBI128
Tablets, Once a day (QD), Per oral
Drug: IBI128
Tablets, Once a day (QD), Per oral
Drug: IBI128
Tablets, Once a day (QD), Per oral
Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
The proportion of subjects in each treatment group with serum uric acid levels <360 μmol/L after continuous treatment for 16 weeks
Time frame: Week 16
The proportion of subjects in each treatment group with serum uric acid levels <300 μmol/L after continuous treatment for 16 weeks
Time frame: Week 16
The proportion of subjects in each treatment group with serum uric acid levels <360, <300 μmol/L after continuous treatment for 2, 4, 8, 12 weeks
Time frame: Week 2, 4, 8, 12
Absolute and percentage Changes in serum uric acid levels from baseline in subjects of each treatment group after continuous treatment for 2, 4, 8, 12, and 16 weeks
Time frame: Baseline, Week 2, 4, 8, 12
The proportion of subjects experiencing gout flares and the number of gout flare occurrences within every 4 weeks from the first dose, among those receiving various doses of Tigulixostat tablets and Febuxostat tablets
Time frame: Baseline through Week 16/18
Number of subjects with Adverse Event, Serious Adverse Events, Treatment Emergent Adverse Event, Adverse event of special interest
Time frame: Baseline through Week 18/20
Number of subjects with clinically significant changes in physical examination results
Clinically significant abnormal physical examination findings reported by the investigator.
Time frame: Baseline through Week 16/18
Number of subjects with clinically significant changes in in vital sign
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure.
Time frame: Baseline through Week 16/18
Number of subjects with clinically significant changes in clinical laboratory parameters
Clinical laboratory parameters including white blood cell, red blood cell, hemoglobin, platelet, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum creatinine, fasting serum glucose, toal bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, serum potassium, creatine phosphokinase, hs-CRP, prothrombin time, thrombin time, activated partial thromboplastin time, international normalized ratio
Time frame: Baseline through Week 16/18
Number of subjects with clinically significant changes in electrodiagram
Electrodiagram parameters including PRinterval, heart rate, RRinterval, corrected QT interval by Fridericia's formula
Time frame: Baseline through Week 16/18
Plasma concentration of Tigulixostat
Time frame: Baseline through Week 16/18
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Dec 2024, 5 months.
Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovent Biologics (Suzhou) Co. Ltd. →